NeoGenomics Inc - Asset Resilience Ratio
NeoGenomics Inc (NEO) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check NeoGenomics Inc (NEO) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2025)
This chart shows how NeoGenomics Inc's Asset Resilience Ratio has changed over time. See NeoGenomics Inc balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down NeoGenomics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is NeoGenomics Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: NeoGenomics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
NeoGenomics Inc Industry Peers by Asset Resilience Ratio
Compare NeoGenomics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.06% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.12% |
|
Spectral Med Inc
TO:EDT |
Diagnostics & Research | 11.67% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for NeoGenomics Inc (2009–2025)
The table below shows the annual Asset Resilience Ratio data for NeoGenomics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | $0.00 | $1.36 Billion | -- |
| 2024-12-31 | 1.21% | $19.83 Million | $1.64 Billion | -3.11pp |
| 2023-12-31 | 4.33% | $72.72 Million | $1.68 Billion | -5.72pp |
| 2022-12-31 | 10.05% | $174.81 Million | $1.74 Billion | -0.57pp |
| 2021-12-31 | 10.62% | $198.56 Million | $1.87 Billion | +3.79pp |
| 2020-12-31 | 6.83% | $67.55 Million | $988.33 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $343.34 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $337.12 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $367.95 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $81.11 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $39.92 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $30.07 Million | -- |
| 2011-12-31 | 2.51% | $500.00K | $19.95 Million | -1.16pp |
| 2010-12-31 | 3.66% | $500.00K | $13.65 Million | -4.06pp |
| 2009-12-31 | 7.72% | $1.00 Million | $12.95 Million | -- |
About NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to dise… Read more